DE69030880D1 - Zusammensetzung zur Stimulierung des Immunsystems - Google Patents

Zusammensetzung zur Stimulierung des Immunsystems

Info

Publication number
DE69030880D1
DE69030880D1 DE69030880T DE69030880T DE69030880D1 DE 69030880 D1 DE69030880 D1 DE 69030880D1 DE 69030880 T DE69030880 T DE 69030880T DE 69030880 T DE69030880 T DE 69030880T DE 69030880 D1 DE69030880 D1 DE 69030880D1
Authority
DE
Germany
Prior art keywords
immune system
stimulating
composition
chemotherapy
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69030880T
Other languages
English (en)
Other versions
DE69030880T2 (de
Inventor
Spiros Jamas
D Easson
Gary Ostroff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alpha Beta Technology Inc
Original Assignee
Alpha Beta Technology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alpha Beta Technology Inc filed Critical Alpha Beta Technology Inc
Publication of DE69030880D1 publication Critical patent/DE69030880D1/de
Application granted granted Critical
Publication of DE69030880T2 publication Critical patent/DE69030880T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Absorbent Articles And Supports Therefor (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Devices For Indicating Variable Information By Combining Individual Elements (AREA)
  • Massaging Devices (AREA)
  • Steroid Compounds (AREA)
  • Liquid Crystal (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)
DE69030880T 1989-09-08 1990-09-05 Zusammensetzung zur Stimulierung des Immunsystems Expired - Fee Related DE69030880T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40476589A 1989-09-08 1989-09-08
PCT/US1990/005022 WO1991003248A2 (en) 1989-09-08 1990-09-05 Method for immune system activation

Publications (2)

Publication Number Publication Date
DE69030880D1 true DE69030880D1 (de) 1997-07-10
DE69030880T2 DE69030880T2 (de) 1997-09-18

Family

ID=23600941

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69030880T Expired - Fee Related DE69030880T2 (de) 1989-09-08 1990-09-05 Zusammensetzung zur Stimulierung des Immunsystems

Country Status (9)

Country Link
US (1) US5504079A (de)
EP (1) EP0491829B1 (de)
JP (1) JPH05502018A (de)
AT (1) ATE153856T1 (de)
AU (1) AU647751B2 (de)
CA (1) CA2067159A1 (de)
DE (1) DE69030880T2 (de)
ES (1) ES2103276T3 (de)
WO (1) WO1991003248A2 (de)

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811542A (en) * 1989-09-08 1998-09-22 Alpha-Beta Technology, Inc. Method for producing soluble glucans
US5622939A (en) * 1992-08-21 1997-04-22 Alpha-Beta Technology, Inc. Glucan preparation
US5488040A (en) * 1989-09-08 1996-01-30 Alpha-Beta Technology, Inc. Use of neutral soluble glucan preparations to stimulate platelet production
JPH05503952A (ja) * 1989-09-08 1993-06-24 アルファ ベータ テクノロジー,インコーポレイティッド 可溶性グルカン類の製造方法
EP0640348A1 (de) * 1993-07-26 1995-03-01 Akzo Nobel N.V. Adjuvansmischung auf Ölbasis und auf Wasserbasis
ATE196609T1 (de) * 1993-07-28 2000-10-15 Diatide Inc Radiomarkierte glukane
NO300692B1 (no) * 1994-04-29 1997-07-07 Biotec Mackzymal As Solubilisert forgrenet ß-1,3-glukan og anvendelse derav samt anvendelse av usolubilisert forgrenet ß-1,3-glukan
US5622940A (en) * 1994-07-14 1997-04-22 Alpha-Beta Technology Inhibition of infection-stimulated oral tissue destruction by β(1,3)-glucan
US6117850A (en) * 1995-08-28 2000-09-12 The Collaborative Group, Ltd. Mobilization of peripheral blood precursor cells by β(1,3)-glucan
US5786343A (en) * 1997-03-05 1998-07-28 Immudyne, Inc. Phagocytosis activator compositions and their use
GB2325233B (en) * 1997-05-16 2001-07-18 Norsk Hydro As Substrates having bound polysaccharides and bacterial nucleic acids
US6046323A (en) * 1997-07-29 2000-04-04 The Collaborative Group, Ltd. Conformations of PPG-glucan
AU6261999A (en) 1998-09-25 2000-04-17 Collaborative Group, Ltd., The Very high molecular weight beta-glucans
US6369216B1 (en) 1998-09-25 2002-04-09 Biopolymer Engineering Pharmaceutical, Inc. Very high molecular weight β-glucans
US6713459B1 (en) * 2000-04-28 2004-03-30 East Tennessee State University Methods for the prophylactic and therapeutic treatment of cardiac tissue damage
US7011845B2 (en) * 2000-05-09 2006-03-14 Mcp Hahnemann University β-glucans encapsulated in liposomes
US7507724B2 (en) 2001-01-16 2009-03-24 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US7906492B2 (en) 2001-01-16 2011-03-15 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US20020123129A1 (en) * 2001-03-01 2002-09-05 Cheung Ling Y. Methods and compositions for degrading nitrogen-containing compounds
US20020123130A1 (en) * 2001-03-01 2002-09-05 Cheung Ling Y. Methods and compositions for degrading polymeric compounds
US20020123127A1 (en) * 2001-03-01 2002-09-05 Cheung Ling Y. Methods and compositions for reducing odor
US6939864B1 (en) 2001-07-09 2005-09-06 Purdue Research Foundation Animal feed compositions and methods of using the same
NO20014256D0 (no) * 2001-09-03 2001-09-03 Bjoern Kristiansen Fremstilling av immunstimulerende forbindelse
US7786094B2 (en) * 2001-10-09 2010-08-31 Biopolymer Engineering, Inc. Use of beta-glucans against biological warfare weapons and pathogens including anthrax
US20040248772A1 (en) * 2001-11-06 2004-12-09 Akikuni Yagita Anticancer compositions
US7256026B2 (en) * 2002-06-28 2007-08-14 Ultra Biotech Limited Oral compositions for white blood cell activation and proliferation
US20040001857A1 (en) * 2002-06-28 2004-01-01 Cheung Ling Yuk Dietary supplements for treating hypertension
US20040005336A1 (en) * 2002-06-28 2004-01-08 Cheung Ling Yuk Dietary supplements for regulating the central nervous system
US20040001859A1 (en) * 2002-06-28 2004-01-01 Cheung Ling Yuk Anti-aging dietary supplements
US20040005335A1 (en) * 2002-06-28 2004-01-08 Cheung Ling Yuk Oral compositions for HIV-infected subjects
US20070042930A1 (en) * 2002-08-13 2007-02-22 Ross Gordon D Effect of beta-glucan on stem cell recruitment and tissue repair
WO2004014320A2 (en) * 2002-08-13 2004-02-19 Biopolymer Engineering, Inc. Methods of using beta glucan as a radioprotective agent
CA2496508C (en) 2002-09-04 2014-04-22 University Of Louisville Research Foundation, Inc. Cancer therapy using beta glucan and antibodies
US20060165700A1 (en) * 2002-09-04 2006-07-27 Ostroff Gary R Cancer therapy using whole glucan particles and antibodies
EP1594418A2 (de) * 2003-01-29 2005-11-16 Immudyne, Inc. Immunstimulierender wirkstoff zur verwendung bei tieren
US7226600B2 (en) * 2003-06-11 2007-06-05 Ultra Biotech Limited Method to prepare compositions comprising yeast treated with electromagnetic energy
US7220416B2 (en) * 2003-06-11 2007-05-22 Ultra Biotech Limited Method to prepare compositions comprising yeast treated with electromagnetic energy
US7223403B2 (en) * 2003-06-11 2007-05-29 Ultra Biotech Limited Method to prepare compositions comprising yeast treated with electromagnetic energy
US7204988B2 (en) * 2003-06-11 2007-04-17 Ultra Biotech Limited Method to prepare compositions comprising yeast treated with electromagnetic energy
US7223400B2 (en) * 2003-06-11 2007-05-29 Ultra Biotech Limited Method to prepare compositions comprising yeast treated with electromagnetic energy
US7214377B2 (en) * 2003-06-11 2007-05-08 Ultra Biotech Limited Method to prepare compositions comprising yeast treated with electromagnetic energy
US7204986B2 (en) * 2003-06-11 2007-04-17 Ultra Biotech Limited Method to prepare compositions comprising yeast treated with electromagnetic energy
US6987012B2 (en) * 2003-06-11 2006-01-17 Ultra Biotech Limited Biological compositions and methods for treatment of colorectal cancer
US7204987B2 (en) * 2003-06-11 2007-04-17 Ultra Biotech Limited Biological compositions and methods for treatment of prostate cancer
US6989253B2 (en) * 2003-06-11 2006-01-24 Ultra Biotech Limited Biological compositions and methods for treatment of testicular cancer
US7208158B2 (en) 2003-06-11 2007-04-24 Ultra Biotech Limited Method to prepare compositions comprising yeast treated with electromagnetic energy
US7201906B2 (en) * 2003-06-11 2007-04-10 Ultra Biotech Limited Method to prepare compositions comprising yeast treated with electromagnetic energy
US7223405B2 (en) * 2003-06-11 2007-05-29 Ultra Biotech Limited Method to prepareompositions comprising yeast treated with electromagnetic energy
US6984507B2 (en) * 2003-06-11 2006-01-10 Ultra Biotech Limited Biological compositions and methods for treatment of lung cancer
US7223404B2 (en) 2003-06-11 2007-05-29 Ultra Biotech Limited Method to prepare compositions comprising yeast treated with electromagnetic energy
US7223401B2 (en) * 2003-06-11 2007-05-29 Ultra Biotech Limited Method to prepare compositions comprising yeast treated with electromagnetic energy
US7223402B2 (en) * 2003-06-11 2007-05-29 Ultra Biotech Limited Method to prepare compositions comprising yeast treated with electromagnetic energy
US6984508B2 (en) 2003-06-11 2006-01-10 Ultra Biotech Limited Biological compositions and methods for treatment of cervical cancer
US20040265990A1 (en) * 2003-06-30 2004-12-30 Cheung Ling Yuk Biological compositions for reduction of E. coli infections
EP1684777A2 (de) * 2003-08-13 2006-08-02 University Of Louisville Research Foundation, Inc. Wirkung von beta-glucan auf die stammzellenrekrutierung und gewebereparatur
US6979562B2 (en) * 2003-11-18 2005-12-27 Ultra Biotech Limited Methods and compositions for treating gastroparesis
US6977168B2 (en) 2003-11-18 2005-12-20 Ultra Biotech Limited Methods and compositions for treating nephrotic syndrome
US6913913B2 (en) 2003-11-18 2005-07-05 Ultra Biotech Limited Methods and compositions for treating renal failure
US6964864B2 (en) * 2003-11-18 2005-11-15 Ultra Biotech Limited Methods and compositions for treating gastritis
US7259001B2 (en) * 2003-11-18 2007-08-21 Ultra Biotech Limited Methods and compositions for treating male sexual dysfunction
US7297522B2 (en) * 2003-11-18 2007-11-20 Ultra Biotech Limited Methods and compositions for treating epilepsy
US20050106166A1 (en) * 2003-11-18 2005-05-19 Cheung Ling Y. Methods and compositions for treating liver cirrhosis
US20050106705A1 (en) * 2003-11-18 2005-05-19 Cheung Ling Y. Methods and compositions for treating hyperlipemia
US6913914B2 (en) 2003-11-18 2005-07-05 Ultra Biotech Limited Methods and compositions for treating hepatitis B
US7078202B2 (en) * 2003-11-18 2006-07-18 Ultra Biotech Limited Methods and compositions for treating vascular dementia
US7197521B2 (en) * 2003-11-21 2007-03-27 Intel Corporation Method and system performing concurrently mark-sweep garbage collection invoking garbage collection thread to track and mark live objects in heap block using bit vector
US20050271613A1 (en) * 2004-03-29 2005-12-08 Toshio Suzuki Beta-1, 3-1, 6-D-glucan and its use
WO2006085895A2 (en) * 2004-05-10 2006-08-17 Biopolymer Engineering, Inc. Whole glucan particles in combination with antibiotics, vaccines and viral monoclonal antibodies
US7740861B2 (en) 2004-06-16 2010-06-22 University Of Massachusetts Drug delivery product and methods
US7514085B2 (en) 2004-07-16 2009-04-07 Medimush A/S Immune modulating compounds from fungi
CN101052383B (zh) 2004-09-17 2013-01-30 马萨诸塞大学 用于溶酶体酶缺乏症的组合物和其用途
WO2006121803A1 (en) 2005-05-05 2006-11-16 Sensient Flavors Inc. Production of beta-glucans and mannans
EP1896600A2 (de) 2005-06-15 2008-03-12 Medimush A/S Gegen krebs gerichtete kombinationsbehandlung und kit
WO2006133708A1 (en) * 2005-06-15 2006-12-21 Medimush A/S Bioactive agents produced by submerged cultivation of a basidiomycete cell
AR056499A1 (es) * 2005-09-06 2007-10-10 Serapis Farmaceuticals Ltd Compuestos
US20090209624A1 (en) * 2005-10-24 2009-08-20 University Of Massachusetts Compositions and their uses for gene therapy of bone conditions
US8323644B2 (en) 2006-01-17 2012-12-04 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
WO2007146440A2 (en) * 2006-06-15 2007-12-21 Biopolymer Engineering, Inc. Dba Biothera, Inc. Glucan preparations
US20080063650A1 (en) * 2006-09-01 2008-03-13 Jun Yan mCRP antagonists and their uses
WO2008027580A2 (en) * 2006-09-01 2008-03-06 University Of Louisville PARTICULATE β-GLUCAN COMPOSITIONS FOR REGULATING DENDRITIC CELLS
WO2008057501A2 (en) * 2006-11-06 2008-05-15 Whitehead Institute Immunomodulating compositions and methods of use thereof
US9457047B2 (en) 2006-11-06 2016-10-04 Whitehead Institute Immunomodulating compositions and methods of use thereof
KR20090009513A (ko) * 2007-07-20 2009-01-23 한국원자력연구원 방사선 조사에 의한 저 분자량의 베타글루칸의 제조 방법및 방사선 조사에 의하여 제조된 저 분자량의 베타글루칸
WO2009042230A1 (en) * 2007-09-27 2009-04-02 Biopolymer Engineering, Inc. Dba Biothera, Inc ß-GLUCAN TREATMENT OF UPPER RESPIRATORY TRACT INFECTION SYMPTOMS AND PSYCHOLOGICAL WELL-BEING
EP2222283A2 (de) 2007-10-29 2010-09-01 University of Massachusetts Zur freisetzung von nukleinsäuren (sirna) mit hefe-zellwandproteinen verkapselte mehrlagige nanopatikel
WO2010008582A2 (en) 2008-07-18 2010-01-21 Rxi Pharmaceuticals Corporation Phagocytic cell drug delivery system
US9493774B2 (en) 2009-01-05 2016-11-15 Rxi Pharmaceuticals Corporation Inhibition of PCSK9 through RNAi
WO2011011617A1 (en) 2009-07-22 2011-01-27 Biothera, Inc. Therapeutic compositions and methods
US9340786B2 (en) 2010-03-24 2016-05-17 Rxi Pharmaceuticals Corporation RNA interference in dermal and fibrotic indications
EP3578183B1 (de) 2010-03-24 2021-09-08 Phio Pharmaceuticals Corp. Rna-interferenz bei augenerkrankungen
US20110293784A1 (en) 2010-05-28 2011-12-01 Anja Wittke Milk-based nutritional compositions
US9242857B2 (en) 2010-08-14 2016-01-26 University Of Massachusetts Yeast cell wall particles for receptor-targeted nanoparticle delivery
WO2015085113A1 (en) 2013-12-04 2015-06-11 Rxi Pharmaceuticals Corporation Methods for treatment of wound healing utilizing chemically modified oligonucleotides
CA2947270A1 (en) 2014-04-28 2015-11-05 Rxi Pharmaceuticals Corporation Methods for treating cancer using nucleic acids targeting mdm2 or mycn
US20170051290A1 (en) 2014-05-01 2017-02-23 Rxi Pharmaceuticals Corporation Methods for treatment of disorders in the front of the eye utilizing nucleic acid molecules
JP6893594B2 (ja) 2014-07-10 2021-06-23 ハイバーセル,インク. 腫瘍微小環境に影響する抗癌剤と組み合わせたβ−グルカン
CN107073294A (zh) 2014-09-05 2017-08-18 阿克赛医药公司 使用靶向tyr或mmp1的核酸治疗老化和皮肤病症的方法
WO2016073763A2 (en) 2014-11-06 2016-05-12 Biothera, Inc. Beta-glucan methods and compositions that affect the tumor microenvironment
EP3234141A4 (de) 2014-12-18 2018-06-20 Alnylam Pharmaceuticals, Inc. Reversir-tm-verbindungen
EP3319614B1 (de) 2015-07-06 2020-12-23 Phio Pharmaceuticals Corp. Gegen superoxid-dismutase 1 (sod1) gerichtete nukleinsäuremoleküle
WO2017007825A1 (en) 2015-07-06 2017-01-12 Rxi Pharmaceuticals Corporation Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
CA3002744A1 (en) 2015-10-19 2017-04-27 Rxi Pharmaceuticals Corporation Reduced size self-delivering nucleic acid compounds targeting long non-coding rna
WO2018156888A1 (en) 2017-02-24 2018-08-30 Biothera Pharmaceuticals, Inc. Beta glucan immunopharmacodynamics
KR20200072886A (ko) 2018-12-13 2020-06-23 주식회사 글루칸 흑효모 유래 바이오폴리머 생산을 위한 배지 조성물 및 그를 이용한 흑효모 유래 바이오폴리머의 제조방법
WO2021064088A1 (en) * 2019-10-04 2021-04-08 Universiteit Gent Beta-glucans having superior immuno-stimulating properties
US20230002766A1 (en) 2019-11-08 2023-01-05 Phio Pharmaceuticals Corp. Chemically modified oligonucleotides targeting bromodomain containing protein 4 (brd4) for immunotherapy
WO2024168010A2 (en) 2023-02-09 2024-08-15 Alnylam Pharmaceuticals, Inc. Reversir molecules and methods of use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5571701A (en) * 1978-11-24 1980-05-30 Sankyo Co Ltd Hydrolyzate polysaccharide, its preparation, and immunoregulator containing hydrolyzate polysaccharide as active ingredient
JPS5676401A (en) * 1979-11-27 1981-06-24 Hitoshi Ito Simple glucan separated from cultured choray, preparation thereof and antitumor agent containing its polysaccharide as effective component
FR2477416A1 (fr) * 1980-03-10 1981-09-11 Unicler Utilisation de hansenula ou d'extraits de hansenula, comme medicament
JPS5945301A (ja) * 1982-09-09 1984-03-14 Toyo Soda Mfg Co Ltd 多糖類及びその製造法
JPS59210901A (ja) * 1983-05-17 1984-11-29 Nippon Kinoko Kenkyusho プロテオグルカン及びそれからなる抗ガン剤
US4810646A (en) * 1984-11-28 1989-03-07 Massachusetts Institute Of Technology Glucan compositions and process for preparation thereof
US4739046A (en) * 1985-08-19 1988-04-19 Luzio Nicholas R Di Soluble phosphorylated glucan

Also Published As

Publication number Publication date
WO1991003248A2 (en) 1991-03-21
US5504079A (en) 1996-04-02
DE69030880T2 (de) 1997-09-18
AU647751B2 (en) 1994-03-31
ES2103276T3 (es) 1997-09-16
EP0491829A1 (de) 1992-07-01
WO1991003248A3 (en) 1991-06-13
JPH05502018A (ja) 1993-04-15
EP0491829B1 (de) 1997-06-04
AU6429290A (en) 1991-04-08
ATE153856T1 (de) 1997-06-15
CA2067159A1 (en) 1991-03-09

Similar Documents

Publication Publication Date Title
DE69030880D1 (de) Zusammensetzung zur Stimulierung des Immunsystems
KR950701350A (ko) 부작용 감소와 동시에 인터페론을 이용한 질환의 치료방법 및 조성물(methods and compositions for the treatment of diseases with interferon while reducing side effects)
LTIP1751A (en) Oral composition for the treatment of inflammatory bowel diseases
EA200600076A1 (ru) Композиции и способы увеличения активности теломеразы
BR0317064A (pt) Administração de células dentrìticas parcialmente amadurecidas in vitro para o tratamento de tumores
Foldi et al. Effect of complex decongestive physiotherapy on gene expression for the inflammatory response in peripheral lymphedema
HU213677B (en) Pharmaceutical compositions for preventing and treating tumor diseases, and process for producing them
AP9801286A0 (en) Therapeutic compounds.
BRPI0409699A (pt) métodos de indução do efeito diurético, de indução, manutenção ou restauração do efeito diurético de diurético não modificador de adenosina, de manutenção, restauração ou melhoria da função renal em paciente, de indução de diurese, de prevenção do inìcio de deficiência renal em paciente com sobrecarga de fluidos ou chf, de tratamento de paciente que sofre de chf e de melhoria dos resultados globais da saúde, composição farmacêutica e seus usos
DE3650505D1 (de) AICA riboside zur prophylaktischen Behandlung von Krankheiten mit einer verminderten Durchblutung.
MXPA00010254A (es) Tratamiento de disfuncion sexual en ciertos grupos de pacientes.
AU5643299A (en) Humic acid and its use in the treatment of various conditions
PL326629A1 (en) Application of flupyrtin in prophylaxy and therapy of deseases associated with damaged hematopoietic cellular system
HUP9903679A2 (hu) Olanzapin alkalmazása bipoláris zavar kezelésére szolgáló gyógyszerkészítmények előállítására
WO2005028608A3 (de) Zellprozessor zur krankheitsbehandlung
ATE207353T1 (de) Verwendung von benzydamin zur behandlung von krankheitszuständen, die durch tnf verursacht werden
DK0859630T3 (da) Kombination af termozolomid og alfa-IFN til behandling af fremskreden cancer
PT1150981E (pt) Composto nucleosidico terapeutico
RU2068266C1 (ru) Способ повышения остроты слуха
GR950100316A (el) Φαρμακευτικο παρασκευασμα βασιζομενο σε αιωρημα εμβρυικων κυτταρων με δραση ανοσοποιητικης υποκαταστασης και μεθοδος θεραπειας του συνδρομου της επικτητης μολυνσης ανοσοποιητικης ανεπαρκειας (hiv) με τη χρηση αυτου του παρασκευασματος.
RU94013606A (ru) Гемостимулятор
DK0788355T3 (da) Anvendelse af intravenøst indgiveligt jern til behandling af tumorsygdomme og/eller infektionssygdomme
MD1135F1 (en) Paradontium treatment method
SE9704451D0 (sv) New method and compositions for the treatment of autoimmune diseases
RU94022334A (ru) Способ лечения и профилактики инвазионных заболеваний

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee